tiprankstipranks
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market
MLTX
MoonLake Immunotherapeutics
RESEARCH TOOLSreports

MoonLake Immunotherapeutics (MLTX) Stock News & Sentiment

645 Followers
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
Premium
Ratings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
21d ago
MLTX
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
Premium
Ratings
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
1M ago
MLTX
MoonLake Highlights Positive S-OLARIS Data and Investor Day
Premium
Company Announcements
MoonLake Highlights Positive S-OLARIS Data and Investor Day
1M ago
8K
MLTX
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
Premium
Ratings
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
2M ago
MLTX
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
Premium
Ratings
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
3M ago
MLTX
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026
Premium
Ratings
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026
3M ago
MLTX
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
Premium
Ratings
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
3M ago
MLTX
More MLTX News >

MLTX News on the Web

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
TipRanks News
Bullish
H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TipRanks News
Bullish
MoonLake's Sonelokimab Achieves 62% HiSCR75 Response at 40 Weeks—Setting a New Benchmark in Hidradenitis Suppurativa Clinical Trials
Market Chameleon
Neutral
MoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75
rttnews
Neutral
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
TipRanks News
Bullish
MoonLake Immunotherapeutics management to meet with BTIG
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
MLTX
Sector Average
Media Buzz
This Week7 articles
Weekly Average4.25 articles
News Sentiment
This Week100%
Sector Average63%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MLTX’s Media Buzz Sentiment?
7 articles about MLTX were published this week. In an average week, 4.25 articles are published.
    What is MLTX’s weekly average amount of articles?
    In an average week, 4.25 articles about MLTX are published.
      What is MLTX’s News Sentiment?
      100% of articles about MLTX were positive this week, compared to its sector average of 63%.
        Healthcare Stocks that are Trending in the News
        6699Angelalign Technology Inc.
        OMEROmeros
        AGIOAgios Pharma
        DMACDiamedica Therapeutics
        DBVTDBV Technologies SA - American
        Showing the stocks with the most bullish news sentiment over the past week